IDEXX Laboratories Inc (IDXX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 59.82% | 59.89% | 59.97% | 59.71% | 59.52% | 59.16% | 58.70% | 58.56% | 58.76% | 58.77% | 58.83% | 58.86% | 58.04% | 57.61% | 57.18% | 56.71% | 56.73% | 56.78% | 56.55% | 56.41% |
| Operating profit margin | 29.97% | 30.06% | 29.82% | 27.13% | 26.69% | 26.09% | 25.77% | 28.49% | 28.99% | 29.28% | 28.35% | 27.92% | 25.66% | 24.12% | 23.96% | 22.95% | 22.97% | 23.50% | 23.14% | 22.71% |
| Pretax margin | 28.99% | 28.84% | 28.49% | 25.83% | 25.54% | 25.11% | 24.89% | 27.61% | 28.07% | 28.32% | 27.34% | 26.76% | 24.44% | 22.88% | 22.70% | 21.74% | 21.69% | 22.15% | 21.69% | 21.24% |
| Net profit margin | 23.08% | 22.93% | 22.52% | 20.38% | 20.17% | 20.05% | 20.07% | 22.43% | 23.17% | 24.14% | 23.89% | 23.59% | 21.49% | 19.20% | 18.59% | 17.78% | 17.77% | 17.99% | 17.78% | 17.33% |
Idexx Laboratories, Inc. has shown consistent and strong profitability over the quarters based on the provided data. The gross profit margin has been consistently high, ranging from 58.56% to 59.97%, indicating efficient cost management and pricing strategies.
The operating profit margin has also exhibited stability, with figures hovering around 26% to 30%. This implies that the company has been effective in controlling its operating expenses while generating revenue from its core operations.
The pretax margin, reflecting the company's profitability before taxes, has been robust, ranging from 24.89% to 28.99%. This indicates that Idexx Laboratories has been able to sustain healthy profits after accounting for operating expenses and interest payments.
Similarly, the net profit margin, which represents the company's bottom line profitability after all expenses have been deducted, has remained strong between 20.05% to 23.08%. This demonstrates Idexx Laboratories' ability to efficiently convert revenue into net income.
Overall, Idexx Laboratories, Inc. has demonstrated consistent profitability across the quarters, showcasing effective cost management, operational efficiency, and strong financial performance.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 33.66% | 34.94% | 36.50% | 33.14% | 32.72% | 33.01% | 32.70% | 35.98% | 38.24% | 38.48% | 35.81% | 34.28% | 30.27% | 30.53% | 30.24% | 29.90% | 30.17% | 31.55% | 30.74% | 30.42% |
| Return on assets (ROA) | 25.92% | 26.66% | 27.57% | 24.90% | 24.72% | 25.36% | 25.47% | 28.33% | 30.56% | 31.72% | 30.17% | 28.97% | 25.35% | 24.30% | 23.47% | 23.16% | 23.34% | 24.14% | 23.62% | 23.22% |
| Return on total capital | 52.33% | 56.39% | 58.59% | 60.63% | 69.05% | 70.54% | 69.66% | 66.04% | 63.64% | 59.90% | 56.56% | 53.86% | 46.61% | 48.34% | 50.58% | 70.06% | 63.12% | 61.46% | 60.82% | 68.15% |
| Return on equity (ROE) | 56.92% | 63.41% | 72.35% | 83.13% | 111.56% | 140.68% | 145.28% | 114.81% | 107.95% | 100.28% | 97.38% | 95.95% | 92.04% | 112.92% | 168.56% | 405.73% | 241.01% | 208.91% | 237.83% | 756.88% |
Idexx Laboratories, Inc. has demonstrated strong profitability ratios over the past quarters. The company's Operating return on assets (Operating ROA) has ranged from 32.70% to 36.50% in the last eight quarters, indicating efficient use of its assets to generate operating income. This trend suggests consistent operational efficiency.
The Return on assets (ROA) has also shown a positive performance, ranging from 24.72% to 27.57% during the same period. This metric illustrates the company's ability to generate profits relative to its total assets.
Furthermore, the Return on total capital has been consistently high, ranging from 45.10% to 49.20% over the quarters, indicating the company's ability to generate returns on its total invested capital efficiently.
The Return on equity (ROE) has been impressive, showing significant growth from 56.92% in Q4 2022 to 83.13% in Q1 2023. This indicates that Idexx Laboratories has been effectively utilizing shareholder equity to generate returns for its investors.
Overall, the profitability ratios of Idexx Laboratories, Inc. suggest a strong and efficient financial performance, highlighting the company's ability to generate profits relative to its assets, capital, and equity.